intravascular

By Targets:	Biochemical Assay Reagents (2) Complement System (1) Drug Metabolite (1) Elastase (3) Factor Xa (1) Isotope-Labeled Compounds (1) Proteasome (1) SARS-CoV (3) Ser/Thr Protease (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Inflammation/Immunology (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-142121

Iopentol

Biochemical Assay Reagents Others

Iopentol is a non-ionic, intravascular contrast media .
HY-B1362

Iopromide

1 Publications Verification

Others Cardiovascular Disease

Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

Iopentol	Biochemical Assay Reagents	Others
Iopentol is a non-ionic, intravascular contrast media .

Iopromide 1 Publications Verification	Others	Cardiovascular Disease
Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

HY-B0385

Gabexate mesylate 4 Publications Verification FOY	Proteasome Factor Xa	Inflammation/Immunology
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with K_is of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with K_is of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

HY-B1362S

Iopromide-d3	Isotope-Labeled Compounds	Cardiovascular Disease
Iopromide-d₃ is the deuterium labeled Iopromide. Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

HY-116462

ONO-EI-601	Drug Metabolite	Others
ONO-EI-601 is the major metabolite of human neutrophil elastase inhibitor ONO-5046. ONO-5046 has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-17443

Sivelestat Maximum Cited Publications 15 Publications Verification EI546; LY544349; ONO5046	Elastase SARS-CoV	Cancer
Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-17443A

Sivelestat sodium Maximum Cited Publications 15 Publications Verification ONO5046-Na; Sodium sivelestat; EI546 sodium; LY544349 sodium	Elastase SARS-CoV	Cancer
Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-17443B

Sivelestat sodium tetrahydrate Maximum Cited Publications 15 Publications Verification EI546 sodium tetrahydrate; LY544349 sodium tetrahydrate; ONO5046 sodium tetrahydrate	Elastase SARS-CoV	Cancer
Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-147297

Pelecopan BCX9930	Complement System	Inflammation/Immunology
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC₅₀ value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .

HY-19101

ONO-3307	Ser/Thr Protease	Cardiovascular Disease
ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases .

HY-109513

Ioxilan	Biochemical Assay Reagents	Others
Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs .

Cat. No.	Product Name

HY-L145

Antihypertensive Compound Library	481 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 481 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

481 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 481 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Chemical Structure

HY-B1362S

Iopromide-d3

Iopromide-d₃ is the deuterium labeled Iopromide. Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.